Literature DB >> 12172061

A case of cerebral infarct in combined antiphospholipid antibody and ovarian hyperstimulation syndrome.

Eun-Jung Koo1, Joung-Ho Rha, Byoung-Ick Lee, Myeong-Ok Kim, Choong-Kun Ha.   

Abstract

Ovarian hyperstimulation syndrome is a serious complication of ovulation induction and has a diverse clinical spectrum from edema to thromboembolism. Antiphospholipid antibody syndrome, one of the well known hypercoagulable states, can be also manifested as an arterial or venous thrombosis and recurrent spontaneous abortion. Sometimes a patient with antiphospholipid antibodies might not notice a miscarriage and seek for assisted reproduction treatment, which harbors a chance of developing ovarian hyperstimulation syndrome. If this happens, the ovarian hyperstimulation syndrome can exacerbate the thrombotic complication of underlying antiphospholipid antibody syndrome, resulting in a catastrophic vascular event. The authors experienced a case of middle cerebral artery infarct, which developed during ovarian hyperstimulation syndrome in a 33-yr-old woman with a previous history of fetal loss. An elevated titer of anticardiolipin antibodies was noticed and persisted thereafter. The authors suggest screening tests for the presence of antiphospholipid antibodies before controlled ovarian hyperstimulation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12172061      PMCID: PMC3054911          DOI: 10.3346/jkms.2002.17.4.574

Source DB:  PubMed          Journal:  J Korean Med Sci        ISSN: 1011-8934            Impact factor:   2.153


  2 in total

Review 1.  Arterial thrombosis in young women after ovarian stimulation: case report and review of the literature.

Authors:  Antonio Girolami; Raffaella Scandellari; Fabiana Tezza; Dalia Paternoster; Bruno Girolami
Journal:  J Thromb Thrombolysis       Date:  2007-01-30       Impact factor: 2.300

2.  Catastrophic antiphospholipid syndrome related to severe ovarian hyperstimulation.

Authors:  V Giner; M R Oltra; M J Esteban; M J García-Fuster; A Salvador; J Núñez; J Redón
Journal:  Clin Rheumatol       Date:  2006-03-15       Impact factor: 3.650

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.